| Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | 07/03 13:05 | businesswire.com |
| Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024 | 06/03 07:00 | businesswire.com |
| Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) | 05/30 07:30 | businesswire.com |
| Xeris to Participate in the Jefferies Global Healthcare Conference | 05/30 07:00 | businesswire.com |
| Xeris Biopharma sees 1Q revenue jump on strength of product sales | 05/09 10:14 | proactiveinvestors.com |
| Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates | 05/09 09:10 | zacks.com |
| Xeris Biopharma and Beta Bionics join forces to develop dual-hormone pump for diabetes | 05/06 10:01 | proactiveinvestors.com |
| Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics | 05/06 07:00 | businesswire.com |
| Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 | 05/02 07:00 | businesswire.com |
| Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | 04/03 16:05 | businesswire.com |